about
TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cellsThe Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCGMouse and human retinoic acid receptor beta 2 promoters: sequence comparison and localization of retinoic acid responsivenessSerum-Induced Differentiation of Glioblastoma Neurospheres Leads to Enhanced Migration/Invasion Capacity That Is Associated with Increased MMP9Cloning and analysis of the mouse Fanconi anemia group A cDNA and an overlapping penta zinc finger cDNA.Global histone modifications predict prognosis of resected non small-cell lung cancer.Do Fanconi anemia genes control cell response to cross-linking agents by modulating cytochrome P-450 reductase activity?Cell death independent of caspases: a review.Apoptosis: target of cancer therapy.Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.Microenvironment involved in FPR1 expression by human glioblastomasCaspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.TRAIL and cancer therapy.Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses.TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.Targeting apoptosis pathways in lung cancer.TGF-β as a therapeutic target in high grade gliomas - promises and challenges.Embryological signaling pathways in Barrett's metaplasia development and malignant transformation; mechanisms and therapeutic opportunities.Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.EMT- and MET-related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities.MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity.The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma.TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis.TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion.The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors.Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells.Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent.Novel cell death mechanisms of trifluorothymidine.Trifluorothymidine induces cell death independently of p53.TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.
P50
Q21260428-11D6B7E3-1BCC-42BB-A938-DBF2C58AAFD8Q24290486-C78336E8-40CA-4782-8EB6-2A00A8A3A390Q28236548-C25FCE9D-7034-4640-B4FE-4A910C5F14D8Q28551757-9C7BA2E3-2AF3-4930-8DE4-65D652BCB201Q30327081-43F38982-A072-487A-8C09-1D060C1C8BABQ33300936-9AB0E1BE-0DFF-45DA-B994-13F6F6D429BFQ34332791-E0204013-32A7-417D-B091-1B96D40BFD3BQ34415492-91913CB5-EE01-40EC-9A92-3547B19B097BQ34735786-9BC308EE-1A54-467D-AE99-E2AA2E0658BFQ34783220-78058C45-F19C-47F9-BEB9-EC27988A987DQ35630434-8196E7D5-AA77-4BA5-80D5-464570F53FCDQ36609796-AACF8CCD-4E85-486A-A2A0-1DC66D0850F0Q37105876-B3BB8778-C061-4D72-B777-9669DEF32FFDQ37601508-9471BDCB-89AA-4F80-B7B7-CBFA77FA4465Q37663068-18044210-933E-4E34-9A59-A84F609EABFCQ37803032-B555E085-1425-4075-9BB2-37BF3DC5A207Q38060439-436A1015-DFAD-49C7-91C5-652B7795BD86Q38220736-3232F732-A279-405E-9B54-4122A0869959Q38242499-00973A6A-0416-47BB-88D8-5C7D4FD1DE8FQ38389066-84C1BA7C-C520-46A9-AB91-388784491EBBQ38677439-12957D75-9E36-490D-B173-272E4385ADE9Q38731552-5853E5C3-5E02-4ED9-8251-F61932BC9E27Q38794171-7FB053B6-6295-4005-B977-C80EE50B2FD4Q38815324-509F24D7-4FBB-4512-81F8-6BF47BD1F6F9Q38857698-56B980AB-DE05-428F-9F3F-5FFF7BDDCF3BQ38919625-A31767CE-C52C-49C6-A5B0-683F6F692059Q38951253-F8E3A73E-326C-4D3B-B60B-1E5CCB9B098AQ39003096-1EF37560-EBC8-4A62-88D0-DBB7CC96E639Q39185966-37855F59-7DBA-4520-A021-08E478B0436CQ39248620-E311D1D0-E568-4F27-B17A-DFB5623E84F7Q39452881-7C7D33A4-B12D-4DD6-8428-FC30C070FC09Q39579208-57AE5766-222F-47F6-9492-0D2F4DAF66C1Q39779639-CD9BC8E9-DB64-48B5-865E-D31E9F4D162CQ39789493-D05BFA16-16E7-48DD-A8E5-0293A31D3BABQ39899386-D94D53CB-5229-4DA7-AE3C-FB300EBF7D79Q39924293-EF55603A-20DA-4FBC-8F22-D6D577A8C488Q39942327-C5941285-D2CA-4261-B2D3-750E005A2294Q39965268-AD6689C6-3E0D-4149-AC14-1F1039E18413Q40109387-4BF89FBE-2B2F-4A03-9396-30E9CA802654Q40158498-2BA7C817-7FC6-4625-ADEA-3D135CAA2FDB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Frank P Vleggaar
@ast
Frank P Vleggaar
@en
Frank P Vleggaar
@es
Frank P Vleggaar
@nl
type
label
Frank P Vleggaar
@ast
Frank P Vleggaar
@en
Frank P Vleggaar
@es
Frank P Vleggaar
@nl
prefLabel
Frank P Vleggaar
@ast
Frank P Vleggaar
@en
Frank P Vleggaar
@es
Frank P Vleggaar
@nl
P106
P21
P2798
P31
P496
0000-0002-2445-9380